CD274 and non-small cell lung carcinoma: Both high [32 (6.36) vs 23881 (33.17) OR 0.14/p<0.05] and ultra-high [5 (0.99) vs 6812 (9.46) OR 0.10/p<0.05] were lower in RETfus+. However, from a cohort of 250 RETfus+ and 42318 RETfus- NSCLC, High positive PD-L1 [100 (40) vs 13542 (32) OR 1.44/p=0.009] was significantly more in RETfus+ NSCLC.